
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity is on track to achieve its guidance for Revtorpyk's commercial shipments to begin in late 3Q26, and the management believes September's announcement will be a real potential catalyst for the stock. Recent data from a physician survey supports a bullish outlook on the launch trajectory and peak sales potential for gedatolisib, and the company has a strong financial position with a cash runway into 2029. Additionally, the Phase 3 VIKTORIA-1 trial showed promising results for both PIK3CA wild-type and mutant tumors, and the company is making progress in its mCRPC program with potential updates in 4Q26. However, risks to the investment thesis include potential commercialization, regulatory, and intellectual property challenges.
Bears say
Celcuity is a clinical-stage biotechnology company that is facing potential challenges with its lead therapeutic candidate, gedatolisib, as the FDA has highlighted concerns about adverse events leading to discontinuations and dose modifications. The company is also facing competition in an increasingly competitive development landscape for treatments in HR+/HER2- metastatic breast cancer. Despite plans for an sNDA submission for the PIK3CA mutant patient population in 3Q26, it is uncertain whether Celcuity will be able to successfully navigate these challenges and achieve commercial success for gedatolisib.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares